Payless Compounders semaglutide injectable recalled for sterility concerns
Payless Compounders is recalling a compounded semaglutide injection due to lack of assurance of sterility. The affected product is a 0.5 mL vial from lot 01-27-2026@14S.5 distributed in Oregon. No injuries have been reported so far.
From the FDA notice · Read the official notice ↗
What to do
- Stop using this product immediately if you have it
- Contact your pharmacy or healthcare provider with the lot number
- Do not use remaining doses from the affected lot
- Ask your provider about alternative treatment options
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
- Sold in
- OR
- Made for
- Adults (0 months and older)
Details
- Units affected
- 91 vials
- Illnesses reported
- None reported
- Manufactured in
- 8505 Sw Creekside Pl Ste 110, N/A, Beaverton, OR, United States
- Classification
- Class II
- Recall number
- D-0471-2026
In the FDA's words
- Description
- Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR Lack of Assurance of Sterility Lot Number 01-27-2026@14S.5 Distribution: OR Affected quantity: 91 vials
- Hazard
- Lack of Assurance of Sterility